Zelira Therapeutics Ltd. · ASX:ZLD
Zelira Therapeutics — Shareholder Meeting (January 2022)
22 slides from Zelira Therapeutics's shareholder meeting presentation, Jan 13, 2022
Slide 1: Zelira Therapeutics AGM 13 January 2022
For personal use only ZELIRA THERAPEUTICS A Global Biopharmaceutical Company Developing and Marketing Clinically Validated Cannabinoid-Based Medicines AGM 13 JANUARY 2022 ASX: ZLD OTCQB:ZLDAF zeliratx.com
Slide 2: Disclaimer & Important Notice
Disclaimer & Important Notice For personal use only Disclaimer Future Matters This presentation has been prepared by Zelira Therapeutics Ltd ACN 103 782 378 (“Company”). It doesnot purport to This presentation contains reference to certain intentions, contain all the information that a prospective i
Slide 3: Your Board
Your Board For personal use only GLOBAL Dr. Oludare Odumosu CEO & Managing Director • Post-clinical development of Iroko Pharmaceutical’s Zorvolex® Tivorbex® and Vivlodex® through FDA approvals and successful US market commercialization. • Founding COO of Ilera Healthcare. Ilera Healthcare was acqui
Slide 4: How to Vote
VOTING How to Vote For personal use only When the poll is open, select the vote icon at the top of the screen Broadcast Vote Q&A Documents Items of business 2A Re-elect Mr Sam Sample as a Director To vote, select either For, Against or Abstain FOR AGAINST ABSTAIN 2B Re-elect Mrs Jane Citizen as a Di
Slide 5: How to ask a Question
QUESTIONS How to ask a Question For personal use only To ask a written question select the To ask a verbal question follow Q & A icon the instructions below the broadcast window. Broadcast Vote Q&A Documents Your question(s) You may enter a question using the field below Select the topic your questi
Slide 6: Chairman's Address
For personal use only Chairman’s Address PAGE 6
Slide 7: CEO & Managing Director's Address
For personal use only CEO & Managing Director’s Address PAGE 7
Slide 8: Company Overview
COMPANY OVERVIEW For personal use only Zelira is a global biopharmaceutical company developing, and marketing clinically validated cannabinoid-based medicines. It offers investors exposure to a rapidly emerging global industry, with multiple shots on goal - to create significant value. PAGE 8
Slide 9: Milestones achieved in FY21
FY21 Milestones achieved in FY21 For personal use only 14 July 2020 16 Sept 2020 2 Dec 2020 15 June 2021 Zelira reports Phase 1 dose Zenivol launched in Zelira partners with Zelira® partners with escalation study in chronic Australia as the world’s SprinJene to launch CBD Health House International
Slide 10: Milestones achieved so far in FY22
FY22 Milestones achieved so far in FY22 For personal use only 12 July 2021 20 October 2021 Zelira US Observational Clinical Zelira® raises US$5 million from Pain Trial receives IRB approval Quincy Street Capital LLC, a US-based family office fund 23 September 2021 Zelira® Launches RAF FIVE™ 3 Novemb
Slide 11: Strong Funding in Place
STRONG FUNDING IN PLACE For personal use only At a group level, funding values Zelira at A$122.8M US$5 million raised from US-based family office fund, Quincy Street Capital LLC US$1.5M A$2.05M US$3.5M A$4.9M via an equity investment in Ilera Derm LLC US$3.5 million (A$4.79 million) via a (Zelira De
Slide 12: R&D Tax Incentive Refund
R&D TAX INCENTIVE REFUND For personal use only Zelda receives a A$1,292,000 Cash refund under the Federal Government’s R&D Tax Incentive Scheme Funds received will be used to support Zelira’s portfolio of products recently launched into global markets and to advance its ongoing clinical development
Slide 13: Zelira Patent Portfolio
Zelira Patent Portfolio For personal use only Zelira’s patent portfolio has been granted or under consideration in 26 countries spanning across the globe. There are 41 patents granted and 103 under prosecution across 9 different therapeutic areas Therapeutic Area Granted/Allowed Under Prosecution/Ex
Slide 14: Multiple Revenue Streams
MULTIPLE REVENUE STREAMS For personal use only Revenue Stream 2 Oral Health Revenue Stream 4 OTC Clinical Trials Toothpaste Rx Additional Products, 2022 Launch Insomnia Opioid Sparing Autism Revenue Stream 3 Dermatology OTC Revenue Stream 1 Revenue Stream 5 Five acne treating Launch & Learn products
Slide 15: Pipeline
PIPELINE Product Status Current Markets Next Steps For personal use only Launched Autism | HOPE 2020 USA AUS GERMANY UK Launched Insomnia | Zenivol® 2020 AUS USA GERMANY UK Launched Oral Care | SprinJene CBD 2021 USA UK ADDITIONAL PRODUCTS Launched Dermatology | RAF FIVE™ 2021 USA IRB approved obser
Slide 16: Formal Business
For personal use only Formal Business PAGE 16
Slide 17: AGM Resolutions: Adoption of Remuneration Report
AGM RESOLUTIONS For personal use only Resolution 1 Option of Remuneration Report To consider and, if thought fit, to pass, with or without amendment, the following as an non-binding resolution: That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, approval is
Slide 18: AGM Resolutions: Ratification of Quincy Street Capital Issue
AGM RESOLUTIONS For personal use only Resolution 2 Ratification of Prior Issue of Securities – Quincy Street Capital To consider and, if thought fit, to pass, with or without amendment, the following as an ordinary resolution: That, for the purposes of ASX Listing Rule 7.4 and for all other purposes
Slide 19: AGM Resolutions: Re-Election of Osagie Imasogie
AGM RESOLUTIONS For personal use only Resolution 3 Re-Election of Director – Osagie Imasogie To consider and, if thought fit, to pass, with or without amendment, the following as an ordinary resolution: That, for the purpose of clause 12.3 of the Constitution, ASX Listing Rule 14.5 and for all other
Slide 20: AGM Resolutions: Re-Election of Lisa Gray
AGM RESOLUTIONS For personal use only Resolution 4 Re-Election of Director – Lisa Gray To consider and, if thought fit, to pass, with or without amendment, the following as an ordinary resolution: That, for the purpose of clause 12.3 of the Constitution, ASX Listing Rule 14.5 and for all other purpo
Slide 21: AGM Resolutions: Approval of 10% Placement Capacity
AGM RESOLUTIONS For personal use only Resolution 5 Approval Of 10% Placement Capacity To consider and, if thought fit, to pass, with or without amendment, the following as an special resolution: That, for the purposes of Listing Rule 7.1A and for all other purposes, approval is given for the Company
Slide 22: Thank You
For personal use only Thank You Zelira Therapeutics Phone +1-484-630-0650 | Email info@zeliratx.com zeliratx.com
Zelira Therapeutics — Shareholder Meeting (January 2022) on 6ix